FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036762757> ?p ?o ?g. }

• W3036762757 endingPage "S91" @default.
• W3036762757 startingPage "S91" @default.
• W3036762757 abstract "Despite the advancement of melanoma care, a subset of melanoma patients do not respond or relapse with current targeted or immuno-therapies. Therefore, it is necessary to explore other biological processes can be therapeutic. The BCL-2 family of proteins contributes to a cancer cell’s resistance to treatment, and BH3 mimetics drugs that target BCL-2 are effective in hematological cancers. We used genetic knockdown and BH3 mimetics therapeutics to target BCL-2’s anti-apoptotic defenses, and identified MCL1 and BCLXL as crucial melanoma pro-survival members. We then examined the effects of combining BH3 mimetics that target MCL1 and BCLXL in vivo and in vitro. We prioritized clinical-trial-ready compounds, such as ABT263 (Navitoclax) and S63845/S64315 (MIK655). We used commercial cell lines, as well as cells derived from patients with difficult-to-treat melanomas. The melanoma panel included the subtypes acral, mucosal, superficial spreading, and nodular, as well as diverse mutations, such as wild type for BRAF, NRAS and NF1. In vitro, the combined inhibition of MCL1 and BCLXL resulted in greater killing than either single agent (p < 0.05) in multiple assays. Genetic knock-down and knock-out studies showed that the combination-induced cell death was not dependent on pro-apoptotic BCL2 family members BID, BIM, or NOXA. Moreover, in mouse xenograft model, the combination inhibited tumor growth of multiple melanomas (p <0.01), had tolerable toxicity, and reduced sphere forming capacity (p < 0.05) in a downstream in vitro assay. In summary, this study suggests that dual targeting of MCL1 and BCLXL can be an alternative treatment for melanoma patients who have exhausted current treatment options." @default.
• W3036762757 created "2020-06-25" @default.
• W3036762757 creator A5000972573 @default.
• W3036762757 creator A5005353330 @default.
• W3036762757 creator A5011682542 @default.
• W3036762757 creator A5012794727 @default.
• W3036762757 creator A5015021082 @default.
• W3036762757 creator A5022583816 @default.
• W3036762757 creator A5024878644 @default.
• W3036762757 creator A5034106929 @default.
• W3036762757 creator A5034522474 @default.
• W3036762757 creator A5048304969 @default.
• W3036762757 creator A5059740087 @default.
• W3036762757 creator A5067205409 @default.
• W3036762757 creator A5069117067 @default.
• W3036762757 creator A5069782695 @default.
• W3036762757 creator A5070390827 @default.
• W3036762757 creator A5076475732 @default.
• W3036762757 creator A5082307785 @default.
• W3036762757 date "2020-07-01" @default.
• W3036762757 modified "2023-10-14" @default.
• W3036762757 title "674 The effective killing of the difficult-to-treat melanomas with the combinations of MCL1 inhibitors S63845/MIK665 plus Navitoclax" @default.
• W3036762757 doi "https://doi.org/10.1016/j.jid.2020.03.686" @default.
• W3036762757 hasPublicationYear "2020" @default.
• W3036762757 type Work @default.
• W3036762757 sameAs 3036762757 @default.
• W3036762757 citedByCount "0" @default.
• W3036762757 crossrefType "journal-article" @default.
• W3036762757 hasAuthorship W3036762757A5000972573 @default.
• W3036762757 hasAuthorship W3036762757A5005353330 @default.
• W3036762757 hasAuthorship W3036762757A5011682542 @default.
• W3036762757 hasAuthorship W3036762757A5012794727 @default.
• W3036762757 hasAuthorship W3036762757A5015021082 @default.
• W3036762757 hasAuthorship W3036762757A5022583816 @default.
• W3036762757 hasAuthorship W3036762757A5024878644 @default.
• W3036762757 hasAuthorship W3036762757A5034106929 @default.
• W3036762757 hasAuthorship W3036762757A5034522474 @default.
• W3036762757 hasAuthorship W3036762757A5048304969 @default.
• W3036762757 hasAuthorship W3036762757A5059740087 @default.
• W3036762757 hasAuthorship W3036762757A5067205409 @default.
• W3036762757 hasAuthorship W3036762757A5069117067 @default.
• W3036762757 hasAuthorship W3036762757A5069782695 @default.
• W3036762757 hasAuthorship W3036762757A5070390827 @default.
• W3036762757 hasAuthorship W3036762757A5076475732 @default.
• W3036762757 hasAuthorship W3036762757A5082307785 @default.
• W3036762757 hasBestOaLocation W30367627571 @default.
• W3036762757 hasConcept C104317684 @default.
• W3036762757 hasConcept C121608353 @default.
• W3036762757 hasConcept C126322002 @default.
• W3036762757 hasConcept C127561419 @default.
• W3036762757 hasConcept C143065580 @default.
• W3036762757 hasConcept C173396325 @default.
• W3036762757 hasConcept C185592680 @default.
• W3036762757 hasConcept C190283241 @default.
• W3036762757 hasConcept C202751555 @default.
• W3036762757 hasConcept C207001950 @default.
• W3036762757 hasConcept C21790070 @default.
• W3036762757 hasConcept C2777658100 @default.
• W3036762757 hasConcept C2778502085 @default.
• W3036762757 hasConcept C2779176958 @default.
• W3036762757 hasConcept C2781187634 @default.
• W3036762757 hasConcept C502942594 @default.
• W3036762757 hasConcept C526805850 @default.
• W3036762757 hasConcept C54355233 @default.
• W3036762757 hasConcept C55493867 @default.
• W3036762757 hasConcept C71924100 @default.
• W3036762757 hasConcept C86803240 @default.
• W3036762757 hasConcept C98274493 @default.
• W3036762757 hasConceptScore W3036762757C104317684 @default.
• W3036762757 hasConceptScore W3036762757C121608353 @default.
• W3036762757 hasConceptScore W3036762757C126322002 @default.
• W3036762757 hasConceptScore W3036762757C127561419 @default.
• W3036762757 hasConceptScore W3036762757C143065580 @default.
• W3036762757 hasConceptScore W3036762757C173396325 @default.
• W3036762757 hasConceptScore W3036762757C185592680 @default.
• W3036762757 hasConceptScore W3036762757C190283241 @default.
• W3036762757 hasConceptScore W3036762757C202751555 @default.
• W3036762757 hasConceptScore W3036762757C207001950 @default.
• W3036762757 hasConceptScore W3036762757C21790070 @default.
• W3036762757 hasConceptScore W3036762757C2777658100 @default.
• W3036762757 hasConceptScore W3036762757C2778502085 @default.
• W3036762757 hasConceptScore W3036762757C2779176958 @default.
• W3036762757 hasConceptScore W3036762757C2781187634 @default.
• W3036762757 hasConceptScore W3036762757C502942594 @default.
• W3036762757 hasConceptScore W3036762757C526805850 @default.
• W3036762757 hasConceptScore W3036762757C54355233 @default.
• W3036762757 hasConceptScore W3036762757C55493867 @default.
• W3036762757 hasConceptScore W3036762757C71924100 @default.
• W3036762757 hasConceptScore W3036762757C86803240 @default.
• W3036762757 hasConceptScore W3036762757C98274493 @default.
• W3036762757 hasIssue "7" @default.
• W3036762757 hasLocation W30367627571 @default.
• W3036762757 hasOpenAccess W3036762757 @default.
• W3036762757 hasPrimaryLocation W30367627571 @default.
• W3036762757 hasRelatedWork W1560634350 @default.
• W3036762757 hasRelatedWork W1561441286 @default.
• W3036762757 hasRelatedWork W1783132379 @default.
• W3036762757 hasRelatedWork W1973794173 @default.

• next